Clinical Trial Update: Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating lucanthone in combination with whole-brain radiation therapy for brain metastases from non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Lucanthone (lucanthone)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Brain Metastases, Non-small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN